Portage Biotech Inc.

NasdaqCM:PRTG Stock Report

Market Cap: US$4.8m

Portage Biotech Dividends and Buybacks

Dividend criteria checks 0/6

Portage Biotech does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-111.2%

Buyback Yield

Total Shareholder Yield-111.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Portage Biotech GAAP EPS of -$0.13

Aug 29

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Jul 20

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Jul 06

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PRTG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTG's dividend payments have been increasing.


Dividend Yield vs Market

Portage Biotech Dividend Yield vs Market
How does PRTG dividend yield compare to the market?
SegmentDividend Yield
Company (PRTG)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (PRTG) (up to 3 years)n/a

Notable Dividend: Unable to evaluate PRTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PRTG's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PRTG has not reported any payouts.


Discover strong dividend paying companies